Wedbush Reaffirms "Outperform" Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VOR - Get Free Report)'s stock had its "outperform" rating reissued by investment analysts at Wedbush in a report released on Thursday,RTT News reports. They presently have a $7.00 price objective on the stock.

Several other equities research analysts have also weighed in on the company. JMP Securities restated a "market outperform" rating and issued a $12.00 target price on shares of Vor Biopharma in a report on Tuesday, December 10th. HC Wainwright restated a "buy" rating and set a $17.50 target price on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vor Biopharma currently has an average rating of "Buy" and a consensus price target of $8.86.

Vor Biopharma Trading Up 1.7 %

NYSE VOR traded up $0.01 during trading on Thursday, reaching $0.88. The company's stock had a trading volume of 210,383 shares, compared to its average volume of 590,640. The stock has a market capitalization of $60.74 million, a PE ratio of -0.54 and a beta of -0.40. Vor Biopharma has a 1-year low of $0.63 and a 1-year high of $2.43. The business has a 50-day moving average price of $1.22 and a 200-day moving average price of $1.01.

Institutional Investors Weigh In On Vor Biopharma

Hedge funds have recently made changes to their positions in the stock. Two Sigma Investments LP raised its holdings in Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after acquiring an additional 25,930 shares in the last quarter. Trustees of Columbia University in the City of New York acquired a new position in shares of Vor Biopharma in the fourth quarter valued at $102,000. RA Capital Management L.P. lifted its position in Vor Biopharma by 74.3% in the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock worth $44,007,000 after purchasing an additional 16,897,159 shares during the period. Northern Trust Corp boosted its stake in Vor Biopharma by 39.0% during the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after buying an additional 44,252 shares in the last quarter. Finally, Lynx1 Capital Management LP bought a new stake in Vor Biopharma in the 4th quarter valued at $707,000. Institutional investors own 97.29% of the company's stock.

Remove Ads

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.